Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249002
Status:
TERMINATED
Last Update Posted:
2019-11-25
First Post:
2005-11-03
Brief Title:
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Pilot Phase II Trial Of ABI-007 A Cremophor El-Free Protein Stabilized Nanoparticle Paclitaxel For The Prevention Of Vascular Access Graft Failure In Patients Undergoing Hemodialysis
Status:
TERMINATED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated due to pipeline prioritization
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure and to obtain preliminary data on the effectiveness of such treatment
Detailed Description:
This is an open-label pilot phase II study to assess the feasibility of administering ABI-007 intravenously IV over 3-5 minutes to patients with hemodialysis graft dysfunction ie either a thrombosed polytetrafluoroethylene PTFE graft or a patent but dysfunctional PTFE graft Patients with graft dysfunction who are successfully treated with angioplasty will start treatment after angioplasty or during their first dialysis through the graft following intervention and will receive 3 subsequent treatments of ABI-007 at 35 mgm2 on weeks 5 13 and 21
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None